Institutional members access full text with Ovid®

Share this article on:

Priming of Hematopoietic Progenitor Cells by Plerixafor and Filgrastim in Children With Previous Failure of Mobilization With Chemotherapy and/or Cytokine Treatment

Sevilla, Julián MD; Schiavello, Elisabetta MD; Madero, Luis MD; Pardeo, Manuela MD; Guggiari, Elena MD; Baragaño, Marta MD; Luksch, Roberto MD; Massimino, Maura MD

Journal of Pediatric Hematology/Oncology: March 2012 - Volume 34 - Issue 2 - p 146–150
doi: 10.1097/MPH.0b013e31821c2cb8
Clinical and Laboratory Observations

Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34+ cell count was below the target of 2×106 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.

*Hospital Infantil Universitario Niño Jesús, Avd Menéndez Pelayo 65, Madrid, Spain

Pediatric Unit, Fondazione IRCCS Istituto Nazionale Tumori

Hematology Department of Oncology, San Raffaele Scientific Institute, Milano

§Division of Rheumatology, Department of Pediatric Medicine, Bambino Gesù Children's Hospital, Rome, Italy

Hospital Quirón, Madrid, Spain

Supported in part by grants from Associazione Bianca Garavaglia (Milano, Italy).

Reprints: Julián Sevilla, MD, HematoOncología Pediátrica, Hospital Infantil Universitario Niño Jesús, Avd Menéndez Pelayo 65, Madrid, 28009, Spain (e-mail: jsevilla.hnjs@salud.madrid.org).

Received October 5, 2010

Accepted March 21, 2011

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.